Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488365 | SCV000575302 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | COL6A3: PM2, BP4 |
Labcorp Genetics |
RCV000821801 | SCV000962573 | likely benign | Bethlem myopathy 1A | 2023-08-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000488365 | SCV002586559 | uncertain significance | not provided | 2022-10-18 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Revvity Omics, |
RCV000488365 | SCV003834186 | uncertain significance | not provided | 2020-01-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004975569 | SCV005564437 | uncertain significance | Inborn genetic diseases | 2024-09-25 | criteria provided, single submitter | clinical testing | The c.4240G>C (p.E1414Q) alteration is located in exon 9 (coding exon 8) of the COL6A3 gene. This alteration results from a G to C substitution at nucleotide position 4240, causing the glutamic acid (E) at amino acid position 1414 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |